171 related articles for article (PubMed ID: 34794435)
1. Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature.
Xu H; Liang Q; Xu X; Tan S; Wang S; Liu Y; Liu L
World J Surg Oncol; 2021 Nov; 19(1):330. PubMed ID: 34794435
[TBL] [Abstract][Full Text] [Related]
2. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature.
Shi Y; Wang M
Thorac Cancer; 2018 Dec; 9(12):1788-1794. PubMed ID: 30379401
[TBL] [Abstract][Full Text] [Related]
3. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
Ou SI; Schrock AB; Bocharov EV; Klempner SJ; Haddad CK; Steinecker G; Johnson M; Gitlitz BJ; Chung J; Campregher PV; Ross JS; Stephens PJ; Miller VA; Suh JH; Ali SM; Velcheti V
J Thorac Oncol; 2017 Mar; 12(3):446-457. PubMed ID: 27903463
[TBL] [Abstract][Full Text] [Related]
4. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
Lai WV; Lebas L; Barnes TA; Milia J; Ni A; Gautschi O; Peters S; Ferrara R; Plodkowski AJ; Kavanagh J; Sabari JK; Clarke SJ; Pavlakis N; Drilon A; Rudin CM; Arcila ME; Leighl NB; Shepherd FA; Kris MG; Mazières J; Li BT
Eur J Cancer; 2019 Mar; 109():28-35. PubMed ID: 30685684
[TBL] [Abstract][Full Text] [Related]
5. Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Dziadziuszko R; Smit EF; Dafni U; Wolf J; Wasąg B; Biernat W; Finn SP; Kammler R; Tsourti Z; Rabaglio M; Ruepp B; Roschitzki-Voser H; Stahel RA; Felip E; Peters S
J Thorac Oncol; 2019 Jun; 14(6):1086-1094. PubMed ID: 30825613
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of Afatinib plus Apatinib using for a lung adenocarcinoma patient with HER-2 V659D mutation: a rare case report.
Sun C; Xu Y; Wang X; Guo Y; Qiu S; Shao G; Yang Z; Liu Y; Zhang P; Ma K
Anticancer Drugs; 2021 Apr; 32(4):469-473. PubMed ID: 33587347
[TBL] [Abstract][Full Text] [Related]
7. Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.
Fang W; Zhao S; Liang Y; Yang Y; Yang L; Dong X; Zhang L; Tang Y; Wang S; Yang Y; Ma X; Wang M; Wang W; Zhao S; Wang K; Gao S; Zhang L
Oncologist; 2020 Mar; 25(3):e545-e554. PubMed ID: 32162827
[TBL] [Abstract][Full Text] [Related]
8. Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation.
Wang J; Wen Y; Ding G; Ding P; Zhang L; Liu J; Zhang T; Yang L
Cancer Biol Ther; 2018 Jun; 19(6):450-453. PubMed ID: 29561699
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
[TBL] [Abstract][Full Text] [Related]
10. A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review.
Liu Y; Li M; Guo Y; Zhang Z; Du L; Zhang X; Wang Y; Zhang D; Xue L; Lei B; Su J; Zhang R; Chen J; Zhang X; Jia Q; Tian C
Pathol Res Pract; 2024 Jul; 259():155371. PubMed ID: 38820929
[TBL] [Abstract][Full Text] [Related]
11. [Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation
to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib].
Huang L; Qin Y; Zhao F; Zhou S; Shi Y
Zhongguo Fei Ai Za Zhi; 2021 Oct; 24(10):739-742. PubMed ID: 34628779
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report.
Park CK; Hur JY; Choi CM; Kim TO; Cho HJ; Shin HJ; Lim JH; Choi YD; Kim YC; Oh IJ
J Korean Med Sci; 2018 Jan; 33(1):e7. PubMed ID: 29215816
[TBL] [Abstract][Full Text] [Related]
13. Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
Oh IJ; Hur JY; Park CK; Kim YC; Kim SJ; Lee MK; Kim HJ; Lee KY; Lee JC; Choi CM
Clin Lung Cancer; 2018 Sep; 19(5):e775-e781. PubMed ID: 30149884
[TBL] [Abstract][Full Text] [Related]
14. Prolonged Response to Afatinib and Crizotinib in a Rare Case of
Plomer E; Früh M; Lauber A; Demmer I; Jochum W; Koster KL
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891886
[TBL] [Abstract][Full Text] [Related]
15. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Mazières J; Barlesi F; Filleron T; Besse B; Monnet I; Beau-Faller M; Peters S; Dansin E; Früh M; Pless M; Rosell R; Wislez M; Fournel P; Westeel V; Cappuzzo F; Cortot A; Moro-Sibilot D; Milia J; Gautschi O
Ann Oncol; 2016 Feb; 27(2):281-6. PubMed ID: 26598547
[TBL] [Abstract][Full Text] [Related]
16. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
Čoupková H; Vyzula R
Klin Onkol; 2018; 31(5):380-383. PubMed ID: 30541326
[TBL] [Abstract][Full Text] [Related]
17. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
Urbán L; Dóczi R; Vodicska B; Tihanyi D; Horváth M; Kormos D; Takács I; Pápai-Székely Z; Póka-Farkas Z; Várkondi E; Schwáb R; Hegedüs C; Vályi-Nagy I; Peták I
Clin Lung Cancer; 2021 Jan; 22(1):e112-e115. PubMed ID: 33082101
[No Abstract] [Full Text] [Related]
18. Pyrotinib for HER2-amplified non-small cell lung cancer patient after progression to Afatinib: a case report.
Zhao H; Yang H; Yu X; Feng H; Yang F
Anticancer Drugs; 2022 Jun; 33(5):509-512. PubMed ID: 35324516
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
Suzawa K; Toyooka S; Sakaguchi M; Morita M; Yamamoto H; Tomida S; Ohtsuka T; Watanabe M; Hashida S; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S
Cancer Sci; 2016 Jan; 107(1):45-52. PubMed ID: 26545934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
